

Carola H Ries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3284150/publications.pdf>

Version: 2024-02-01

26
papers

3,721
citations

331670

21
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

7141
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated macrophages promote intratumoral conversion of conventional CD4 ⁺ T cells into regulatory T cells via PD-1 signalling. <i>OncImmunology</i> , 2022, 11, 2063225.	4.6	14
2	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma. <i>Cancers</i> , 2021, 13, 2400.	3.7	28
3	Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	24
4	Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	44
5	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 541-551.	7.1	66
6	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN γ /IL-2-Mediated Manner. <i>Cancer Immunology Research</i> , 2020, 8, 1180-1192.	3.4	19
7	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. <i>European Journal of Cancer</i> , 2020, 141, 162-170.	2.8	29
8	CD163 ⁺ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. <i>Clinical and Translational Immunology</i> , 2020, 9, e1108.	3.8	47
9	Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles. <i>Cell Reports</i> , 2019, 27, 3062-3080.e11.	6.4	118
10	Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 1280-1297.	7.3	126
11	Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. <i>Nature Cell Biology</i> , 2019, 21, 511-521.	10.3	121
12	Periostin Limits Tumor Response to VEGFA Inhibition. <i>Cell Reports</i> , 2018, 22, 2530-2540.	6.4	33
13	T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	229
14	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 859-876.	8.5	150
15	Effects of IL-10 and Th 2 cytokines on human M1 phenotype and response to CSF1R inhibitor. <i>Journal of Leukocyte Biology</i> , 2018, 103, 545-558.	3.3	6
16	A drug development perspective on targeting tumor-associated myeloid cells. <i>FEBS Journal</i> , 2018, 285, 763-776.	4.7	31
17	Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses. <i>Journal of Immunology</i> , 2018, 201, 2273-2286.	0.8	38
18	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, 5, 53.		688

#	ARTICLE	IF	CITATIONS
19	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <i>Cancer Cell</i> , 2016, 30, 377-390.	16.8	141
20	Macrophage Susceptibility to Emdactuzumab (RG7155) Treatment. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 3077-3086.	4.1	57
21	Suppression of microRNA activity amplifies IFN- β -induced macrophage activation and promotes anti-tumour immunity. <i>Nature Cell Biology</i> , 2016, 18, 790-802.	10.3	214
22	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Reports</i> , 2016, 14, 1748-1760.	6.4	90
23	CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. <i>Current Opinion in Pharmacology</i> , 2015, 23, 45-51.	3.5	107
24	Targeting tumor-associated macrophages in cancer therapy and understanding their complexity. <i>Onc Immunology</i> , 2014, 3, e955356.	4.6	27
25	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	16.8	1,033
26	In Vitro Generation of Monocyte-Derived Macrophages under Serum-Free Conditions Improves Their Tumor Promoting Functions. <i>PLoS ONE</i> , 2012, 7, e42656.	2.5	193